guest ::
| Home > Publications database > Inhibitors of GapN-dependent NADPH supply as potential lead compounds for novel therapeutics against Streptococcus pyogenes > print |
| Home > Publications database > Inhibitors of GapN-dependent NADPH supply as potential lead compounds for novel therapeutics against Streptococcus pyogenes > print |
| 001 | 646213 | ||
| 005 | 20260217210828.0 | ||
| 024 | 7 | _ | |a 10.1080/21505594.2025.2609393 |2 doi |
| 024 | 7 | _ | |a 2150-5594 |2 ISSN |
| 024 | 7 | _ | |a 2150-5608 |2 ISSN |
| 024 | 7 | _ | |a 10.3204/PUBDB-2026-00758 |2 datacite_doi |
| 037 | _ | _ | |a PUBDB-2026-00758 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Schütt, Isabell |0 0009-0002-3996-7166 |b 0 |
| 245 | _ | _ | |a Inhibitors of GapN-dependent NADPH supply as potential lead compounds for novel therapeutics against Streptococcus pyogenes |
| 260 | _ | _ | |a Austin, Tex. |c 2026 |b Landes Bioscience |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1771330836_907078 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Infections with Streptococcus pyogenes are among the most important diseases caused by bacteria and are responsible for around 500,000 deaths every year. In 2024, macrolide-resistant S. pyogenes was added to the WHO’s list of priority pathogens. The non-phosphorylating glyceraldehyde-3-phosphate dehydrogenase GapN has been identified as a potential drug target in S. pyogenes. SpyGapN is the major NADP-reducing enzyme in these bacteria as they lack the oxidative part of the pentose phosphate pathway. In this study, in silico docking of compound libraries to the glyceraldehyde 3-phosphate binding pocket of SpyGapN was used to screen for potential competitive inhibitors. Among the candidates identified with this approach, 1,2-dihydroxyethane-1,2-disulfonate (glyoxal bisulfite) showed the strongest inhibition of SpyGapN activity in vitro. In a complementary approach, crystallographic fragment screening was conducted, which identified the ultra-low-molecular-weight compounds pyrimidine-5-amine and 4-hydroxypyridazine targeting the cofactor-binding pocket of SpyGapN. Both low-molecular-weight compounds were experimentally confirmed to inhibit the activity of purified SpyGapN. Combinations of glyoxal bisulfite with either pyrimidine-5-amine or 4-hydroxypyridazine enhanced the inhibitory effect of SpyGapN. Glyoxal bisulfite was able to kill S. pyogenes. This effect was accelerated by combining glyoxal bisulfite with 4-hydroxypyridazine. While these findings suggest that inhibition of SpyGapN probably contributes to the observed antibacterial activity, the exact mechanism of action remains to be confirmed, as the compounds also affect other G3P-converting enzymes. Nevertheless, these compounds provide a promising starting point for the development of more specific SpyGapN inhibitors. |
| 536 | _ | _ | |a 6G3 - PETRA III (DESY) (POF4-6G3) |0 G:(DE-HGF)POF4-6G3 |c POF4-6G3 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: bib-pubdb1.desy.de |
| 693 | _ | _ | |a PETRA III |f PETRA Beamline P13 |1 EXP:(DE-H253)PETRAIII-20150101 |0 EXP:(DE-H253)P-P13-20150101 |6 EXP:(DE-H253)P-P13-20150101 |x 0 |
| 700 | 1 | _ | |a Einwohlt, Philip |b 1 |
| 700 | 1 | _ | |a Wandinger, Anna-Maria |b 2 |
| 700 | 1 | _ | |a Teuffel, Jonathan |b 3 |
| 700 | 1 | _ | |a Wirsing, Regina |b 4 |
| 700 | 1 | _ | |a Hlawatschke, Ben H. |b 5 |
| 700 | 1 | _ | |a Fehlauer, Hanna L. |b 6 |
| 700 | 1 | _ | |a Bothe, Sebastian |b 7 |
| 700 | 1 | _ | |a Bader, Nicole |b 8 |
| 700 | 1 | _ | |a Monaci, Emanuele |b 9 |
| 700 | 1 | _ | |a Kreikemeyer, Bernd |0 0000-0001-9527-5098 |b 10 |
| 700 | 1 | _ | |a Schindelin, Hermann |b 11 |
| 700 | 1 | _ | |a Wade, Rebecca C. |b 12 |
| 700 | 1 | _ | |a Fiedler, Tomas |0 P:(DE-HGF)0 |b 13 |e Corresponding author |
| 773 | _ | _ | |a 10.1080/21505594.2025.2609393 |g Vol. 17, no. 1, p. 2609393 |0 PERI:(DE-600)2657572-3 |n 1 |p 2609393 |t Virulence |v 17 |y 2026 |x 2150-5594 |
| 856 | 4 | _ | |u https://www.tandfonline.com/doi/full/10.1080/21505594.2025.2609393#d1e551 |
| 856 | 4 | _ | |u https://bib-pubdb1.desy.de/record/646213/files/Inhibitors%20of%20GapN-dependent%20NADPH%20supply%20as%20potential%20lead%20compounds%20for%20novel%20therapeutics%20against%20Streptococcus%20pyogenes.pdf |y OpenAccess |
| 856 | 4 | _ | |u https://bib-pubdb1.desy.de/record/646213/files/Inhibitors%20of%20GapN-dependent%20NADPH%20supply%20as%20potential%20lead%20compounds%20for%20novel%20therapeutics%20against%20Streptococcus%20pyogenes.pdf?subformat=pdfa |x pdfa |y OpenAccess |
| 909 | C | O | |o oai:bib-pubdb1.desy.de:646213 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 913 | 1 | _ | |a DE-HGF |b Forschungsbereich Materie |l Großgeräte: Materie |1 G:(DE-HGF)POF4-6G0 |0 G:(DE-HGF)POF4-6G3 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-600 |4 G:(DE-HGF)POF |v PETRA III (DESY) |x 0 |
| 914 | 1 | _ | |y 2026 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2025-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2025-11-11 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2025-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2025-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2025-11-11 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b VIRULENCE : 2022 |d 2025-11-11 |
| 915 | _ | _ | |a Creative Commons Attribution-NonCommercial CC BY-NC 4.0 |0 LIC:(DE-HGF)CCBYNC4 |2 HGFVOC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2024-08-08T20:19:27Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2024-08-08T20:19:27Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2025-11-11 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2025-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2025-11-11 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2025-11-11 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2025-11-11 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b VIRULENCE : 2022 |d 2025-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2025-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2025-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2025-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2025-11-11 |
| 920 | 1 | _ | |0 I:(DE-H253)EMBL-User-20120814 |k EMBL-User |l EMBL-User |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-H253)EMBL-User-20120814 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|